Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Care Access Launches Heart & Kidney Health Screening Initiative in Kennesaw to Address Undetected Heart & Kidney Health Risks

Event for Kennesaw Community Aims to Detect Heart Risks Most People Don’t Know They Have

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Kennesaw, Ga. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Despite the prevalence of Lp(a) and its impact on cardiovascular health, most people are unaware of their Lp(a) levels due to limited access to testing. It is critical to raise community awareness of this risk factor as there are no currently approved medicines for lowering Lp(a) and it is not impacted by a healthy diet or exercise.

The Heart & Kidney Health Screening offers no-cost Lp(a) testing as well as screenings for other related metabolism and kidney risks. The screenings are part of the Future of Medicine program by Care Access which not only provides crucial health information to participants but also encourages community involvement in clinical trials for potential new treatments targeting Lp(a) and other conditions.

The Future of Medicine program features three key components:

  • No-Cost Testing: No-cost screenings for certain heart and kidney risks, including Lp(a), to provide individuals valuable information about their health.
  • Health Education: Information to raise awareness about cardiovascular health and the importance of clinical research in advancing medical treatments.
  • Clinical Trial Awareness: Assistance in finding local clinical trial opportunities and promoting community engagement in medical research.

Care Access will host screening events on November 13-16 at The 1808, located at 2871 Cherokee Street NW in Kennesaw, Ga. Walk-ins are available, but scheduling is recommended at MyFreeHeartTest.com.

"The limited availability of testing for Lp(a) has been a concern in our field for too long. This initiative not only provides testing but also educates the community on the risks associated with elevated levels," said Dr. Sinikka Green, Medical Director and Principal Investigator at Care Access.

Care Access has a clinical research facility in Decatur to bring more research opportunities closer to Atlanta area residents.

About Care Access

Care Access is a global clinical research company helping to accelerate the future of medicine. With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) on-demand staffing, space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.

Care Access will host screening events on November 13-16 at The 1808, located at 2871 Cherokee Street NW in Kennesaw, Ga.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.